Molbio Diagnostics reappoints K.S. Kamalakara & Co as cost auditors for FY27
- Molbio Diagnostics reappointed M/s K. S. Kamalakara & Co as cost auditors for FY27
- The firm is based in Bengaluru and holds Firm Registration No. 000296
- Board approved the reappointment on September 25, 2026
- CMA K. S. Kamalakara leads the firm with over two decades of experience

*this image is generated using AI for illustrative purposes only.
Molbio Diagnostics Limited has reappointed M/s K. S. Kamalakara & Co, Cost Accountants, as its cost auditors for the financial year 2026-27. The decision was taken by the Board of Directors during a meeting held on September 25, 2026.
The reappointment was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The firm, registered with Firm Registration No. 000296, is a peer-reviewed entity based in Bengaluru, India.
Auditor Profile and Expertise
M/s K. S. Kamalakara & Co is described in the disclosure as a prominent and professionally managed firm of Cost Accountants. The firm specializes in a range of compliance and accounting services, including:
- GST and indirect taxation
- Cost accounting and cost audits
- Financial accounting
- Import-export policy and customs
- Export benefit claims and FEMA compliances
- Litigation support and project report preparation
The firm is led by its founding partner, CMA K. S. Kamalakara (M.Com., FCMA). He is a Fellow Cost Accountant with over two decades of experience in cost records, audits, indirect taxation, and corporate litigation matters.
Disclosure Details
The company provided the following details regarding the appointment in its regulatory filing:
| Particulars | Details |
|---|---|
| Reason for change | Re-appointment of M/s. Kamalakara & Co as cost auditors |
| Date of re-appointment | September 25, 2026 |
| Term of appointment | Financial year 2026-27 |
| Firm Registration No. | 000296 |
The Board meeting commenced at 11:26 am and concluded at 11:35 am. The intimation was also made available on the company's website in compliance with Regulation 46 of the SEBI LODR Regulations, 2015.
Historical Stock Returns for Molbio Diagnostics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.67% | -2.39% | +4.61% | +55.46% | +55.46% | +55.46% |
How might the reappointment of the same cost auditor impact Molbio Diagnostics' long-term cost optimization strategies for FY2026-27?
What are the potential implications of this compliance decision on investor confidence regarding Molbio's corporate governance standards?
Could the continuity of K. S. Kamalakara & Co influence Molbio's upcoming capital expenditure plans or product pricing structures?





























